Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery for Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histopathologically confirmed newly diagnosed glioblastoma multiforme or Anaplastic Glioma (WHO Grade III) by surgical excision or biopsy.~2. Patient must recover from the effects of surgery, post-operative infection, or other complications.~3. Therapy should start within 5 weeks of surgery~4. Must have an estimated survival of \> 8 weeks.~5. KPS \< 70.~6. Age \> 65 years.~7. Must have a pre- and post operative contrast enhanced MRI scans~8. Laboratory values within the following limits: ANC (absolute neutrophil count) \>/= 1500 cell/ul Platelets \>/= 100x 10(3)/ul, Hemoglobin \>/= 9g/dl, Serum Creatinine ≤ 1.5mg/dl., Serum total Bilirubin \</= 1.5 x upper limit of normal (ULN), SGOT/SGPT \</= 2.5x ULN, Albumin \>/= 3g/dl.~   -~Exclusion Criteria:~1. Histology grade less than Anaplastic Glioma ( WHO Grade III).~2. Recurrent malignant glioma.~3. Tumor involving the Brain stem.~4. Any detected tumor foci beyond the cranial vault.~5. Major medical or psychiatric illness, which in the investigator's opinion will prevent administration or completion of the protocol therapy.~6. Prior malignancies, except for non-melanomatous skin cancers, or carcinoma in situ of uterus, cervix or bladder, unless disease free for \> 5 years.~7. Prior chemotherapy for the current disease.~   -

- Gender: ALL
- Minimum Age: 66 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyberknife (Type: OTHER): Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).